EZH2在肾癌组织和肾癌细胞系中的表达及意义

Expression and Clinical Significance of EZH2 in Renal Cell Carcinoma and Renal Cell Carcinoma Cell Lines

目的:探讨EZH2蛋白在肾癌和肾癌细胞系中的表达情况及其与肾癌发生发展的关系。方法:应用Western blot检测12例肾癌和正常肾组织及两种细胞系ACHN和786-0中EZH2蛋白的表达,采用免疫组化法检测64例肾癌和12例正常肾组织中EZH2蛋白的表达情况,并分析与肾癌临床病理特征的关系。结果:Westernblot检测结果显示,EZH2蛋白在正常肾小管上皮细胞系HK 2的表达极低,而肾癌细胞系786-0和ACHN的表达水平较高;正常肾组织EZH2蛋白表达阴性,肾癌组织均有不同程度的表达,差异有统计学意义(P<0.05)。免疫组化结果示,肾癌和正常肾组织EZH2蛋白表达率分别为78.1%和16.7%,差异有统计学意义(P<0.01)。EZH2蛋白表达率在局限性和局部进展性肾癌分别为63.9%和92.9%,差异有统计学意义(P<0.01);EZH2蛋白表达率在肾癌不同病理分级组和是否淋巴结转移组间差异有统计学意义(P<0.05)。结论:EZH2异常表达与肾癌的分期、分级和淋巴结转移有关,与肾癌的临床进展关系密切。

Objective：To investigate the expression and significance of EZH2 in renal cell carcinoma （RCC） and renal cell carcinoma cell lines. Methods：The expression of EZH2 was detected in 12 RCC and normal renal tissues by using western blot. We also evaluated two RCC cell lines for EZH2 protein expression using western blot. EZH2 protein expression was assessed by immunohistochemistry in 64 RCC and 12 normal renal tissues. Results： The expression level of EZH2 in human HK 2 cells was very low, but was high in two RCC cell lines. There were signifi- cant differences in EZH2 protein levels between normal renal and RCC tissues （P〈0.05）. Immunohistochemistry results revealed EZH2 protein was detectable in 16.7 % and 78.1% of normal renal and RCC tissues,respectively （P〈0.01）. The positive expression rate of EZH2 was 63.9% and 92.9% in localized RCC and locally advanced RCC groups, respectively, and showed astatistieally significant difference （P〈0.01）. The positive expression rates of EZH2 also showed astatistically significant difference in RCC groups with different pathological grades and lymph node metastasis profiles （P〈0.05）. Conclusions：The abnormal expression of EZH2 is associated with RCC clinical stage, pathologic grade and lymph node metastasis. The dysfunction of EZH2 may play an important role in the carcinogenesis and progression of RCC.